Delfi Diagnostics

Delfi Diagnostics is a biotechnology company focused on innovative cancer detection methods using advanced machine learning algorithms to analyze fragments of cell-free DNA from a single blood sample. The company’s approach scans millions more data points than conventional methods, identifying previously unrecognized cancer-associated DNA fragments, and deriving deeper clinical insights. Delfi Diagnostics is currently enrolling approximately 15,000 participants in its clinical trial, CASCADE-LUNG, to further validate its technology. The company’s FirstLook blood test offers a convenient, accessible, and personalized approach to lung cancer screening, boasting a negative predictive value of 99.8%. Additionally, Delfi Diagnostics is committed to developing new products to address significant unmet medical needs and has published promising proof-of-concept data in other cancer types. The company is also building evidence to support the use of its platform for monitoring and minimal residual disease (MRD) applications. Delfi Diagnostics operates labs and offices in Baltimore, MD, and Palo Alto, CA, and supports hybrid and remote work options for most positions. The company offers comprehensive employee benefits, including 100% coverage of medical premiums for employees and their families, 16 weeks of paid parental leave, a non-accrual time off program, a generous holiday schedule, and a one-time $400 subsidy for home office setup. Delfi Diagnostics also provides wide-ranging learning and development programs. The company’s technology was first published in Nature in 2019, and it has since formed collaborations with OSF HealthCare, City of Hope, and Memorial Sloan Kettering Cancer Center to improve lung cancer screening rates and advance cancer screening technology. In July 2022, Delfi Diagnostics raised $225 million in Series B financing, following $100 million in Series A financing in January 2021. The company was selected as the liquid biopsy partner for the 4-IN-THE-LUNG-RUN European lung cancer screening study and announced the availability of a new fragmentome-based cancer treatment monitoring assay in February 2024.